Cross-Wire Time Confirmation: For verification purposes and Universal time-stamp confirmation please note that the following news was released at 4:09pm EST, after market close on November 13, 2012. Originally, …

VANCOUVER, BRITISH COLUMBIA- (November 13, 2012) – Pacific Therapeutics Ltd. (the "Issuer") is a development stage specialty pharmaceutical company focused on the identification and development …

Researchers conducting a trial have found that a bone marrow transplant from a donor who is only half-matched genetically can cure sickle cell.

Following is a summary of current health news briefs. Novartis drug helps patients with rare inflammatorydiseases ZURICH (Reuters) – Novartis' Ilaris helps reducepatients' symptoms and the frequency of attacks in two rareinflammatory diseases, …

ZURICH (Reuters) – Swiss pharmaceutical company Novartis said on Monday its Certican, an immune system drug also known under the names Afinitor and Votubia, showed positive outcomes in a two-year phase III study in liver transplantation. The study, whi…

Gilead Sciences Reports Interim Data From Ongoing Phase 2 ELECTRON Trial

HAIFA, Israel — Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapies, announced today the Company has successfully completed the integration and testing of its new scaled-up …

WINSTON-SALEM, N.C., Nov. 5, 2012 /PRNewswire/ — Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that the United States Patent and Trademark Office (USPTO) has issued a …

THOUSAND OAKS, Calif., Nov. 3, 2012 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced results of the Phase 3 EVOLVE™ (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which …

Optimer Pharmaceuticals has started an advanced trial of its drug Dificid to prevent C. diff diarrhea in bone marrow transplant patients.